1 / 6

Global Collaboration 39 countries, 1034 sites, 18,201 patients

Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation in East Asia with Atrial Fibrillation. S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L . Wallentin7, D . Xavier8 , JH . Alexander4

synclair-osvaldo
Download Presentation

Global Collaboration 39 countries, 1034 sites, 18,201 patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Efficacy and Safety of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation in East Asia with Atrial Fibrillation S. Goto1, J. Zhu2, L. Lisheng2, BH. Oh3, D. Wojdyla4, M. Hanna5, J. Horowitz6, L. Wallentin7, D. Xavier8, JH. Alexander4 (1) Tokai University School of Medicine, Isehara, Japan (2) Fuwai Hospital, Beijing, China, People's Republic of (3) Seoul National University Hospital, Seoul, Korea, Republic of (4) Duke Clinical Research Institute, Duke University Medical Center, Durham, United States of America (5) Bristol-Myers Squibb, Princeton, United States of America (6) University of Adelaide, Adelaide, Australia (7) Uppsala University, UCR-Uppsala Clinical Research Center, Uppsala, Sweden (8) St. John's Research Institute, Bangolore, India

  2. Global Collaboration39 countries, 1034 sites, 18,201 patients 1,993 patients were recruited from East Asian countries including China (n=843), Japan (n=336), South Korea (n=310), Philippines(n=205), Malaysia (n=126), Hong Kong (n=76) and Singapore (n=40) Poland: 314 Finland: 26 Sweden: 217 Hungary: 455 Norway: 90 Romania: 274 Russia: 1800 Canada: 1057 Ukraine: 956 Denmark: 339 U.K.: 434 Turkey: 6 Netherlands: 309 United States: 3433 Japan: 336 Belgium: 194 China: 843 South Korea: 310 Germany: 854 Mexico: 609 India: 601 France: 35 Taiwan: 57 Spain: 230 Hong Kong: 76 Czech Rep: 165 Philippines: 205 Austria: 34 Colombia: 111 Malaysia: 126 Italy: 178 Singapore: 40 Brazil: 700 Israel: 344 Peru: 213 Chile: 258 Australia: 322 South Africa: 89 Argentina: 1561 Bristol-Myers Squibb and Pfizer

  3. Primary Efficacy Endpoint

  4. Primary Safety Endpoint

  5. Primary Safety Endpoint

  6. Conclusion- East Asia vs Non East Asia • The ARISTOTLE trial enrolled over 1900 patients from East Asian countries. These patients were of lower body weight and tended to have poorer INR control with warfarin. • Despite similar CHADS2 scores, the overall rate of stroke was higher in East Asian than non-East Asian patients. • Apixaban had consistent benefits when compared with warfarin on stroke or systemic embolism in East Asian and non-East Asian patients. • A tendency toward a greater reduction in bleeding was seen with apixaban compared with warfarin in East Asian compared with non-East Asian patients. • Rates of intracranial bleeding on warfarin were higher in East Asian than non-East Asian patients. • These data support that apixaban is an attractive alternative to warfarin among East Asian as well as non-East Asian patients with nonvalvular AF.

More Related